Compare Amgen, Inc. (AMGN) vs Church & Dwight Co., Inc. (CHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Church & Dwight Co., Inc. — how do they compare? Amgen, Inc. trades at $361.93 (market cap $196.12B), while Church & Dwight Co., Inc. trades at $98.28 (market cap $22.83B). The key difference: Amgen, Inc. is far larger — about 8.6× Church & Dwight Co., Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | CHD | |
|---|---|---|
Market Cap | $196.12B | $22.83B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $105.26 |
52-Week Low | $271.18 | $81.60 |
Enterprise Value | $241.41B | $24.53B |
Dividend Yield | 2.77% | 1.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Church & Dwight (CHD) trades at $96.36, up 0.72% today, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 adjusted EPS of $0.95, exceeding expectations, driven by 5% organic sales growth. Recent acquisition of Miss Mouth's brand for $325 million aims to strengthen its fabric care portfolio. Cash flow trends show a net outflow in 2025, though operating cash flow remains robust at $1.22 billion.
Outlook remains positive with a consensus price target of $101.33, implying 5% upside, supported by strong analyst sentiment (53% buy ratings). Risks include margin pressure from inflation and competitive threats in consumer staples. The stock's valuation at 31.7x P/E requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →
